Stockscreener 앱 받기
5.12
0.20%
0.010
시간 외 거래:
5.12
전일 마감가:
$5.11
열려 있는:
$4.99
하루 거래량:
46,760
Relative Volume:
0.97
시가총액:
$184.60M
수익:
$15.33M
순이익/손실:
$-40.19M
주가수익비율:
-2.922
EPS:
-1.7522
순현금흐름:
-
1주 성능:
-10.49%
1개월 성능:
-1.92%
6개월 성능:
+28.00%
1년 성능:
-46.78%
1일 변동 폭
$4.66
$5.29
1주일 범위
$4.66
$5.88
52주 변동 폭
$3.50
$10.24
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
명칭
Trisalus Life Sciences Inc
전화
415 336 8917
주소
6272 WEST 91ST AVENUE, WESTMINSTER
TLSI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
5.12 | 184.60M | 15.33M | -40.19M | 0 | -1.7522 |
|
ABT
Abbott Laboratories
|
132.60 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.24 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
381.36 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.45 | 107.01B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.11 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | Lake Street | Buy |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-11 | 개시 | ROTH MKM | Buy |
| 2024-10-25 | 개시 | Northland Capital | Outperform |
| 2024-09-16 | 개시 | Oppenheimer | Outperform |
| 2024-05-30 | 개시 | Canaccord Genuity | Buy |
모두보기
Trisalus Life Sciences Inc 주식(TLSI)의 최신 뉴스
Geode Capital Management LLC Purchases 3,710 Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) - Defense World
Northland maintains TriSalus stock with $12.50 target - Investing.com Australia
Northland maintains TriSalus stock with $12.50 target By Investing.com - Investing.com India
TLSI Reports Strong Revenue Growth in First Quarter of 2025 | TL - GuruFocus
TriSalus Life Sciences (TLSI) Secures $22M Investment and Plans Capital Restructuring | TLSI Stock News - GuruFocus
TriSalus Life Sciences secures $22 million in funding By Investing.com - Investing.com India
TriSalus Life Sciences secures $22 million in funding - Investing.com
TriSalus Life Sciences Announces $22.0 Million Private Placement Preliminary Q1 2025 Unaudited Financial Results - Business Wire
TriSalus Life Sciences files to offer up to 3.34M shares - MSN
TriSalus Life Sciences announces board member resignation By Investing.com - Investing.com Canada
TriSalus Life Sciences announces board member resignation - Investing.com Australia
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives $11.56 Average Price Target from Analysts - Defense World
TriSalus Life Sciences, Inc. SEC 10-K Report - TradingView
VAREX IMAGING (VREX) Moves 16.5% Higher: Will This Strength Last? - Yahoo Finance
TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock? - Nasdaq
Uveal Neoplasms Treatment Market Size in 7MM is expected to grow - openPR.com
TriSalus Life Sciences (TLSI) Expected to Announce Quarterly Earnings on Monday - Defense World
TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates - MSN
TriSalus Life Sciences Reports Strong Growth Amid Challenges - MSN
Canaccord Genuity Group Reiterates Buy Rating for TriSalus Life Sciences (NASDAQ:TLSI) - Defense World
TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks - Seeking Alpha
TriSalus Life Sciences’ (TLSI) “Buy” Rating Reiterated at Canaccord Genuity Group - The AM Reporter
Earnings call transcript: TriSalus Life Sciences Q4 2024 sees 44% revenue growth - Investing.com India
Trisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetration - MSN
TriSalus Life Sciences Reports Strong 2024 Growth - TipRanks
TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic - Asianet Newsable
Earnings call transcript: TriSalus Life Sciences Q4 2024 sees 44% revenue growth By Investing.com - Investing.com South Africa
TriSalus Life Sciences Confirms Positive Outlook For FY25Update - Nasdaq
TriSalus Life Sciences Inc Reports Q4 Revenue of $8.3M, Exceedin - GuruFocus
TriSalus Life Sciences, Inc. Q4 Loss Decreases, But Misses Estimates - Nasdaq
TRISALUS LIFE SCIENCES Earnings Results: $TLSI Reports Quarterly Earnings - Nasdaq
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update - Marketscreener.com
Examining the Future: TriSalus Life Sciences's Earnings Outlook - Benzinga
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping - Marketscreener.com
Medicare Approves $11K+ Reimbursement for TriNav Cancer Treatment SystemMajor Win for Hospitals - Stock Titan
TRISALUS LIFE SCIENCES Earnings Preview: Recent $TLSI Insider Trading, Hedge Fund Activity, and More - Nasdaq
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System - Business Wire
TriSalus Life Sciences (TLSI) Projected to Post Earnings on Thursday - Defense World
TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code - Business Wire
TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Down 10.7% – Here’s What Happened - Defense World
Can This Revolutionary Liver Cancer Treatment Double Drug Effectiveness? New Study Shows Remarkable Results - StockTitan
Short Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Expands By 75.3% - Defense World
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of “Buy” from Analysts - Defense World
TriSalus Life Sciences announces executive departure By Investing.com - Investing.com South Africa
TriSalus Life Sciences announces executive departure - Investing.com India
Trisalus Life Sciences Inc (TLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
11.62%
0.20%
자본화:
|
볼륨(24시간):